CANC
Exchange-traded product on NASDAQ (US)
- Type
- Exchange-traded product
- Share class
- —
- Status
- listed
- ISIN
- —
- Currency
- —
- Represents the company
- No
Holdings as of Aug 31, 2026
The full portfolio as of the quarter end Aug 31, 2026, from the fund's report to the SEC (Form N-PORT, filed Oct 30, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of May 31, 2026.
59 lines, 56 linked, weights sum to 100.05% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| Revolution Medicines Inc | RVMD US76155X1000 | Equity | 61,768 | −24,682 | 6.02% | $ 12.698M |
| Eli Lilly & Co | LLY US5324571083 | Equity | 9,404 | +1,720 | 5.15% | $ 10.878M |
| Cogent Biosciences Inc | COGT US19240Q2012 | Equity | 283,440 | +77,021 | 4.70% | $ 9.92M |
|
Roche Holding AG
|
RHHBY US7711951043 | Equity | 164,068 | +22,415 | 4.17% | $ 8.81M |
|
Novartis AG
|
NOVN CH0012005267 | Equity | 52,465 | +5,445 | 3.79% | $ 8M |
| Bristol-Myers Squibb Co | BMY US1101221083 | Equity | 112,924 | +11,244 | 3.57% | $ 7.544M |
| Merck & Co Inc | MRK US58933Y1055 | Equity | 50,878 | −2,100 | 3.56% | $ 7.518M |
| AbbVie Inc | ABBV US00287Y1091 | Equity | 27,338 | +4,638 | 3.32% | $ 7.01M |
| Halozyme Therapeutics Inc | HALO US40637H1095 | Equity | 63,165 | +30,567 | 3.19% | $ 6.726M |
| BeOne Medicines Ltd | ONC US07725L1026 | Equity | 18,669 | +7,164 | 3.18% | $ 6.713M |
| Johnson & Johnson | JNJ US4781601046 | Equity | 24,555 | +4,655 | 3.09% | $ 6.528M |
| Immunome Inc | IMNM US45257U1088 | Equity | 230,958 | −84,690 | 3.00% | $ 6.331M |
| Genmab A/S | GMAB US3723032062 | Equity | 183,357 | +24,496 | 2.88% | $ 6.08M |
| CG oncology Inc | CGON US1569441009 | Equity | 77,547 | +8,845 | 2.76% | $ 5.828M |
| Ideaya Biosciences Inc | IDYA US45166A1025 | Equity | 142,271 | +6,424 | 2.70% | $ 5.705M |
| Exelixis Inc | EXEL US30161Q1040 | Equity | 101,461 | +4,576 | 2.63% | $ 5.544M |
| Bridgebio Pharma Inc | BBIO US10806X1028 | Equity | 64,261 | −8,930 | 2.33% | $ 4.922M |
| Amgen Inc | AMGN US0311621009 | Equity | 10,097 | −922 | 2.06% | $ 4.34M |
| Enliven Therapeutics Inc | ELVN US29337E1029 | Equity | 74,478 | +16,281 | 2.04% | $ 4.312M |
| AstraZeneca PLC | AZN GB0009895292 | Equity | 25,983 | −7,518 | 2.00% | $ 4.214M |
| Legend Biotech Corp | LEGN US52490G1022 | Equity | 197,934 | +3,842 | 1.95% | $ 4.113M |
| Zai Lab Ltd | ZLAB US98887Q1040 | Equity | 161,278 | −35,694 | 1.95% | $ 4.106M |
| Celcuity Inc | CELC US15102K1007 | Equity | 42,837 | −4,613 | 1.81% | $ 3.815M |
| Erasca Inc | ERAS US29479A1088 | Equity | 208,197 | +60,369 | 1.76% | $ 3.723M |
| Relay Therapeutics Inc | RLAY US75943R1023 | Equity | 185,142 | +24,066 | 1.61% | $ 3.403M |
| Iovance Biotherapeutics Inc | IOVA US4622601007 | Equity | 403,718 | +123,670 | 1.56% | $ 3.298M |
| Zymeworks Inc | ZYME US98985Y1082 | Equity | 110,609 | +4,994 | 1.54% | $ 3.253M |
| Nuvation Bio Inc | NUVB US67080N1019 | Equity | 416,638 | +21,325 | 1.31% | $ 2.775M |
| UroGen Pharma Ltd | URGN IL0011407140 | Equity | 61,279 | +2,761 | 1.25% | $ 2.641M |
| Arcus Biosciences Inc | RCUS US03969F1093 | Equity | 87,067 | +3,927 | 1.21% | $ 2.549M |
| Kura Oncology Inc | KURA US50127T1097 | Equity | 171,385 | new +171,385 | 1.03% | $ 2.168M |
| Gilead Sciences Inc | GILD US3755581036 | Equity | 14,646 | −46 | 1.02% | $ 2.143M |
| Tyra Biosciences Inc | TYRA US90240B1061 | Equity | 85,323 | +69,543 | 1.01% | $ 2.136M |
| Summit Therapeutics Inc | SMMT US86627T1088 | Equity | 150,035 | +28,938 | 0.97% | $ 2.043M |
| Corvus Pharmaceuticals Inc | CRVS US2210151005 | Equity | 142,722 | +34,245 | 0.95% | $ 2.004M |
| Natera Inc | NTRA US6323071042 | Equity | 6,084 | +1,846 | 0.93% | $ 1.959M |
| Tango Therapeutics Inc | TNGX US87583X1090 | Equity | 81,952 | new +81,952 | 0.89% | $ 1.872M |
| AnaptysBio Inc | ANAB US0327241065 | Equity | 32,744 | +1,474 | 0.88% | $ 1.867M |
| Immatics NV | IMTX NL0015285941 | Equity | 179,617 | +8,118 | 0.81% | $ 1.712M |
| Replimune Group Inc | REPL US76029N1063 | Equity | 108,413 | new +108,413 | 0.79% | $ 1.659M |
| Immunocore Holdings PLC | IMCR US45258D1054 | Equity | 44,900 | +14,051 | 0.77% | $ 1.631M |
| Cullinan Therapeutics Inc | CGEM US2300311063 | Equity | 65,785 | +2,959 | 0.69% | $ 1.452M |
| Guardant Health Inc | GH US40131M1099 | Equity | 8,773 | −2,213 | 0.66% | $ 1.395M |
| ORIC Pharmaceuticals Inc | ORIC US68622P1093 | Equity | 99,043 | +41,066 | 0.61% | $ 1.287M |
| Candel Therapeutics Inc | CADL US1374041093 | Equity | 86,337 | new +86,337 | 0.53% | $ 1.128M |
| Syndax Pharmaceuticals Inc | SNDX US87164F1057 | Equity | 54,962 | −17,250 | 0.50% | $ 1.06M |
| Janux Therapeutics Inc | JANX US47103J1051 | Equity | 53,953 | +2,431 | 0.47% | $ 983.024K |
| Inhibrx Biosciences Inc | INBX US45720N1037 | Equity | 7,084 | −3,086 | 0.43% | $ 897.543K |
| Olema Pharmaceuticals Inc | OLMA US68062P1066 | Equity | 83,532 | +3,773 | 0.41% | $ 871.239K |
| Bicara Therapeutics Inc | BCAX US0554771032 | Equity | 37,499 | new +37,499 | 0.41% | $ 866.977K |
| BridgeBio Oncology Therapeutic | BBOT US1079241022 | Equity | 97,750 | +4,411 | 0.41% | $ 860.2K |
| CytomX Therapeutics Inc | CTMX US23284F1057 | Equity | 241,337 | +12,350 | 0.38% | $ 810.892K |
| Arvinas Inc | ARVN US04335A1051 | Equity | 88,095 | +3,971 | 0.38% | $ 810.474K |
|
First American Treasury Obliga
|
FXFXX US31846V3289 | Money market | 807,908.68 | −1,112,400.27 | 0.38% | $ 807.909K |
| First Tracks Biotherapeutics I | TRAX US3371851029 | Equity | 19,205 | −39,214 | 0.38% | $ 803.537K |
| Moderna Inc | MRNA US60770K1079 | Equity | 5,247 | new +5,247 | 0.35% | $ 736.364K |
| Adlai Nortye Group Ltd | ANL US00704R1095 | Equity | 46,444 | +2,090 | 0.31% | $ 659.04K |
| ArriVent Biopharma Inc | AVBP US04272N1028 | Equity | 21,729 | −21,015 | 0.31% | $ 652.956K |
| Autolus Therapeutics PLC | AUTL US05280R1005 | Equity | 268,127 | new +268,127 | 0.30% | $ 630.098K |